OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the
standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with
breast cancer whose disease has advanced on one endocrine therapy in combination with a
CDK4/6 inhibitor.